Astrazeneca plc AZN.US Overview Analysis
)AZN AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock excels in value rating and ranks among the top in dividend scores. It's a prime choice for long-term accumulation. For optimal entry, check our trend and swing trading ratings.
AZN Current Performance
2.74%
Astrazeneca plc
3.56%
Avg of Sector
1.47%
S&P500
Top 10 High Relevance to AZN
- NVS Novartis agValue 4Trend 4Swing Trading 4Whale Interest 2Dividend 5See more
AZN Profile
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.